Mallinckrodt Pharmaceuticals
MNK
#10563
Rank
โ‚น0.41 B
Marketcap
โ‚น31.52
Share price
0.00%
Change (1 day)
N/A
Change (1 year)

P/E ratio for Mallinckrodt Pharmaceuticals (MNK)

P/E ratio as of April 2026 (TTM): -0.0028

According to Mallinckrodt Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.00280971.

P/E ratio history for Mallinckrodt Pharmaceuticals from 2022 to 2023

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
21.8-776,678.37%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
34.2-1,217,464.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Zogenix
ZGNX
-6.56 233,208.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
24.3-863,466.68%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.